Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient

Leukemia. 2005 May;19(5):869-70. doi: 10.1038/sj.leu.2403723.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Boronic Acids / adverse effects*
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Hearing Loss, Bilateral / chemically induced*
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Pyrazines / adverse effects*
  • Pyrazines / therapeutic use

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib